Exagen Diagnostics Names Thomas O'Connor Vice President, Sales

Apr 10, 2006, 01:00 ET from Exagen Diagnostics, Inc.

    ALBUQUERQUE, N.M., April 10 /PRNewswire/ -- Exagen Diagnostics, Inc.,
 which develops and commercializes genomic marker-based in vitro diagnostic
 (IVD) kits for predicting risk of recurrence or treatment response, today
 announced that Thomas O'Connor has joined the company as vice president,
 sales. Based in Exagen's Austin, Texas, office, O'Connor oversees all sales
 and managed care personnel and will have worldwide responsibility as Exagen
 expands its sales force in the coming year.
     "Thomas has an outstanding record of sales success in the clinical
 diagnostics arena, and we welcome his expertise as Exagen prepares to
 launch its breast cancer products within the next year," said Exagen CEO
 James McClintic.
     O'Connor has 20 years of sales, sales team leadership, management and
 business development experience, during which he consistently exceeded
 targets and grew business and market share several times the industry
 average. Prior to joining Exagen, O'Connor held positions as business
 development manager and North America sales manager for Beckman Coulter,
 Inc., which manufactures clinical diagnostics and biomedical testing
 instrument systems, tests and supplies. He also served as director of sales
 and marketing at Quantachrome Instrument Corp. and has held sales positions
 at Varian Instruments, Leeman Labs, Inc., Coulter Corp. and Micromeritics
 Instrument Corp. O'Connor holds a B.S. in chemistry/biology from State
 University of New York.
     About Exagen Diagnostics, Inc.
     An emerging leader in the development of predictive in vitro diagnostic
 (IVD) kits, Exagen is uniquely able to discover, validate and productize
 small sets of genomic markers for use in oncology, infectious disease and
 other indications. The company's first tests predict the risk of breast
 cancer recurrence, so that women with a low or elevated risk of recurrence
 can be identified with high accuracy. Exagen plans to submit its first test
 to the Food and Drug Administration for clearance later this year, and will
 be the first to market a set of genomic markers to predict breast cancer
 recurrence using a fluorescent in situ hybridization (FISH) kit. For more
 information, visit http://www.exagen.com.

SOURCE Exagen Diagnostics, Inc.